Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.89 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245003 | 1.00 | ADAMTS5 (1.00) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5217054 | 0.94 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5216899 | 0.94 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5217062 | 0.94 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5218721 | 0.94 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5216898 | 0.94 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5218728 | 0.94 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL6720209 | 0.94 | AKR1B1 (0.93) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5221174 | 0.94 | AKR1B1 (0.93) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL19736251 | 0.94 | AKR1B1 (1.00) | ADAMTS5AKR1B1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954815-B1 | PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION | GLYCOFI INC (US) | 2015-02-25 | — | — | EP | claimed |
| US-8501438-B2 | Production of glycoproteins with reduced O-glycosylation | GLYCOFI, INC. (US) | 2013-08-06 | — | — | US | claimed |
| US-20120237973-A1 | PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION | GLYCOFI, INC. (US) | 2012-09-20 | — | — | US | claimed |
| US-8206949-B2 | Production of glycoproteins with reduced O-glycosylation | GLYCOFI, INC. (US) | 2012-06-26 | — | — | US | claimed |
| US-20090170159-A1 | PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION | GLYCOFI, INC (US) | 2009-07-02 | — | — | US | claimed |
| EP-1954815-A2 | PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION | Glycofi, Inc. (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061631-A2 | PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION | GLYCOFI, INC (US) | 2007-05-31 | — | — | WO | claimed |
| US-12084651-B2 | Surface display of whole antibodies in eukaryotes | MERCK SHARP & DOHME LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-11959118-B2 | Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc-region | MERCK SHARP & DOHME LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240011016-A1 | FULL-LENGTH HUMAN IMMUNOGLOBULIN G ANTIBODY LIBRARIES FOR SURFACE DISPLAY AND SECRETION IN SACCHAROMYCES CEREVISIAE | MERCK SHARP & DOHME LLC (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2022109084-A1 | FULL-LENGTH HUMAN IMMUNOGLOBULIN G ANTIBODY LIBRARIES FOR SURFACE DISPLAY AND SECRETION IN SACCHAROMYCES CEREVISIAE | MERCK SHARP & DOHME CORP. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210317441-A1 | SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES | MERCK SHARP & DOHME CORP. (US) | 2021-10-14 | — | — | US | disclosed |
| US-11046951-B2 | Surface display of whole antibodies in eukaryotes | MERCK SHARP & DOHME CORP. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1313471-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002017915-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | ADAMTS5 2515/4885AKR1B1 281/4885PTPN1 312/4885 |
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | SLC5A2, OXSR1, SLC5A1 | ADAMTS5 4556/4885AKR1B1 594/4885PTPN1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.